Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
Teva Vs. Viatris: Who Will Dominate In President Trump's America?
12:18pm, Friday, 17'th Oct 2025
Teva Pharmaceuticals and Viatris occupy leading positions in the generic drugs market, valued at more than $613 billion in 2030. Each of them has advantages and "dark spots" in their portfolios of FDA
Here's Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Strong Value Stock
10:40am, Thursday, 16'th Oct 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder
11:16am, Monday, 13'th Oct 2025
Teva secures FDA approval for Uzedy label expansion to treat adults with bipolar I disorder.
Billionaire Stanley Druckenmiller has earned a spot among the best investors ever. Through more than four decades of investing, Druckenmiller has yet to post a year where his investments finished in t
PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (E
Teva Pharmaceutical: Turnaround Driven By Huge Pipeline Upside
04:07am, Tuesday, 07'th Oct 2025
Teva Pharmaceutical Industries Limited is regaining investor interest as restructuring efforts drive margin improvements and unlock pipeline potential. Turnaround: company is changing to a more profit
For a lot of investors, earnings season is the highlight of every quarter. It's the roughly six-week period where most S&P 500 components report their operating results and give investors an inside lo
Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term
10:41am, Tuesday, 30'th Sep 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025
04:30pm, Thursday, 25'th Sep 2025
TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial re
Teva Releases Q3 2025 Aide Memoire
04:30pm, Thursday, 25'th Sep 2025
TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2025 Aide Memoire is available on the “Investors” page on
Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors
11:42am, Thursday, 25'th Sep 2025
Wall Street is slowly beginning to understand that Teva Pharmaceutical Industries Limited is rapidly transforming from a generic medication supplier into one of the key players in the CNS treatment ma
Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2025 Transcript
07:23am, Wednesday, 24'th Sep 2025
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Bank of America Global Healthcare Conference 2025 September 24, 2025 4:00 AM EDT Company Participants Richard Francis - President, CEO & Director Co
Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?
01:21pm, Tuesday, 23'rd Sep 2025
ALVO's partnership-driven model fuels surging biosimilar revenues, while TEVA leans on scale but faces debt and competitive pressures.
Teva Pharmaceutical Industries Limited - Special Call
02:53pm, Monday, 22'nd Sep 2025
Teva Pharmaceutical Industries Limited - Special Call Company Participants Christopher Stevo - Senior Vice President of Investor Relations & Competitive Intelligence Eric Hughes - Executive VP of Glob
PARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the pres
